Company / Interest Expense
Compass Therapeutics, Inc. Interest Expense History
FY2018-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
-
FY2022
5-year range
$0 / $908.0K
FY2018-FY2022
Trend
-100.0%
vs FY2021
Sector context
#39 of 42
Health Care
What the data says
Improved from $908,000 to $0 over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 42
▼
Key checks
Key Insights
- Compass Therapeutics, Inc.'s interest expense has declined for 3 consecutive years.
- In FY2022, interest expense decreased 100.0% year-over-year.
- Peak interest expense was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $0 | -100.0% |
| FY2021 | $370.0K | -59.3% |
| FY2020 | $908.0K | -26.1% |
| FY2019 | $1.2M | +37361.9% |
| FY2018 | $3.3K | - |
As of FY2022 · SEC 10-K · Updated Feb 28, 2026